Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for EDTA chelation therapy as a treatment for atherosclerosis, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS chelation therapy coverage policy has a long history, and this modification keeps the core position intact: EDTA chelation therapy for atherosclerosis remains non-covered under Medicare. This policy does not list specific CPT or HCPCS codes in the available data — but that doesn't reduce your exposure. Claims for chelation services in cardiovascular contexts still land on Medicare's radar, and denials are routine. If your practice or billing team handles integrative medicine, cardiology, or any specialty where chelation comes up, this update deserves your attention before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Ethylenediamine-Tetra-Acetic (EDTA) Chelation Therapy for Treatment of Atherosclerosis |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium — high denial risk for practices that bill chelation services to Medicare patients |
| Specialties Affected | Integrative medicine, cardiology, internal medicine, naturopathic medicine (where licensed) |
| Key Action | Audit your charge capture for chelation-related services and confirm no Medicare claims go out for atherosclerosis-related chelation after May 15, 2026 |
CMS EDTA Chelation Therapy Coverage Criteria and Medical Necessity Requirements 2026
CMS has maintained a consistent position on this for years: EDTA chelation therapy is not considered medically necessary for the treatment of atherosclerosis under Medicare. This modified coverage policy, effective May 15, 2026, does not reverse that position. It reaffirms it.
The core medical necessity argument from CMS is straightforward. The clinical evidence supporting chelation as a cardiovascular treatment does not meet Medicare's threshold for coverage. Even accounting for the TACT trial (Trial to Assess Chelation Therapy), CMS has not moved to a covered status for this indication. The agency's standard has been — and remains — that the evidence is insufficient to conclude chelation is safe and effective for atherosclerosis at a population level.
For billing purposes, this means any claim for EDTA chelation therapy tied to an atherosclerosis diagnosis will not survive Medicare review. That's not a maybe. Submitting those claims isn't just a denial risk — it's a compliance risk. If your billing team is uncertain about where the line falls between covered chelation uses (like lead poisoning) and non-covered uses (cardiovascular disease), talk to your compliance officer before May 15, 2026.
Prior authorization won't help here. This isn't a service that gets covered with a prior auth approval. CMS excludes it categorically for this indication. No amount of documentation changes that.
CMS EDTA Chelation Therapy Exclusions and Non-Covered Indications
The non-covered designation here is specific to atherosclerosis. That's the critical distinction your billing team needs to understand.
EDTA chelation does have legitimate, covered uses — heavy metal poisoning being the primary one. Lead poisoning, iron overload, and certain other toxic metal conditions can support coverage under Medicare when medical necessity criteria are met. The problem arises when chelation is billed under a cardiovascular or atherosclerosis-related diagnosis. That's where CMS draws the hard line.
This distinction matters operationally. If your practice offers chelation for any indication, your coders need to tie the correct diagnosis to the service. A claim for chelation billed alongside an ICD-10 code for coronary artery disease or peripheral vascular disease — even if chelation wasn't the primary treatment — can trigger a denial or an audit. Code to what you actually treated and why.
The real issue here is upcoding risk. Some practices bill chelation for cardiovascular patients and use heavy metal toxicity as the supporting diagnosis when the clinical picture doesn't support it. That's not a billing strategy. That's fraud exposure. If you're not sure how your practice handles this, loop in your compliance officer now.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| EDTA chelation for atherosclerosis | Not Covered | Not specified in policy data | CMS considers this experimental/unproven for cardiovascular disease |
| EDTA chelation for heavy metal poisoning (e.g., lead) | Covered (separate policy) | Not specified in this policy | Medical necessity documentation required; billed under toxicity diagnosis |
| EDTA chelation for other cardiovascular indications | Not Covered | Not specified in policy data | Applies across Medicare fee-for-service; no prior auth pathway |
Note: This policy does not list specific CPT or HCPCS codes. See the Affected Codes section for guidance.
CMS EDTA Chelation Therapy Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your charge capture before May 15, 2026. Pull every claim your team has submitted in the past 12 months that includes chelation-related services for Medicare patients. Flag any tied to cardiovascular or atherosclerosis diagnoses. Know your exposure before the effective date. |
| 2 | Train your coders on the covered vs. non-covered distinction. Chelation for heavy metal toxicity is different from chelation for atherosclerosis. Your coders need to apply the right diagnosis code every time — not default to a cardiovascular code because that's the patient's primary condition. |
| 3 | Do not submit Medicare claims for chelation therapy tied to atherosclerosis or coronary artery disease after May 15, 2026. This is a categorical non-covered service for this indication. There is no prior authorization pathway, no appeals shortcut, and no documentation that flips it to covered. |
| 4 | Review your ABN (Advance Beneficiary Notice) process. If your practice offers chelation to Medicare patients for cardiovascular reasons, you must issue an ABN before the service. The patient needs to understand Medicare will not pay, and they're accepting financial responsibility. Skipping this step creates billing and compliance problems. |
| 5 | Check your Medicare Advantage contracts separately. This CMS policy governs traditional Medicare fee-for-service. Medicare Advantage plans set their own coverage rules. Some may align with CMS. Others may differ. Verify each plan's position on chelation before assuming the same rule applies. |
| 6 | Talk to your compliance officer if chelation is a regular part of your service mix. EDTA chelation billing for atherosclerosis sits in a high-scrutiny zone. CMS and Medicare Administrative Contractors (MACs) watch for patterns. If this service represents meaningful volume at your practice, get a compliance review done now. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for EDTA Chelation Therapy Under This Policy
This policy does not list specific CPT, HCPCS, or ICD-10 codes in the available data. Do not treat that as a gap in enforcement — CMS applies this non-coverage position regardless of which code is used to bill chelation services for atherosclerosis.
Common Codes Associated With Chelation Billing (For Reference — Not From Policy Data)
Because the policy itself doesn't specify codes, your billing team should be aware of the codes commonly used in chelation billing contexts. These are not confirmed by the policy document — consult your MAC's local coverage determination (LCD) resources and billing guidelines for code-level specifics.
For chelation therapy services, billing typically runs through infusion administration codes and the chelating agent itself. Your MAC may have issued an LCD that provides more granular code-level guidance than this national policy. Check your MAC's website directly.
What to Do Without a Code List
The absence of a specific code list in this policy is common for CMS non-coverage determinations. The policy applies to the service and indication — not to a specific code. That means:
- Claim denial can happen regardless of which administration code you use
- The diagnosis code driving the non-coverage is atherosclerosis-related (coronary artery disease, peripheral arterial disease, and similar cardiovascular diagnoses)
- Your MAC may have issued a local coverage determination with more specific code guidance — check with your Medicare Administrative Contractor directly
If your practice is billing chelation services to Medicare in any capacity, pull your MAC's LCDs now. The national policy sets the floor. The MAC's LCD may add detail.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.